COVID-19NCT05207293
Pilot Test of COVID-19 Related Clinical Outcome Assessment Methodology and Qualitative Evidence of Content Validity
An observational study of COVID-19, run by Synairgen Research Ltd. at 5 sites in 2 countries.
Trial summary
COVID-19 is an acute respiratory disease caused by Severe Acute Respiratory Syndrome coronavirus (SARS-CoV). Synairgen is currently conducting a global Phase III clinical trial of SNG001 to determine efficacy and safety in patients hospitalised due to COVID-19 that receive oxygen therapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID-19
- How many people
- 29 participants
- Where
- 5 sitesin 2 countries
- Study dates
- 15 Nov 2021to 31 Jan 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study will include up to 25 patients who have had a positive test for COVID-19 and who were hospitalised due to their COVID-19. Diagnosis of COVID-19 and hospitalization will be confirmed by study personnel. The interview will take place up to 35 days post discharge from hospital. The eligibility criteria are designed to align with the SG018 protocol to ensure that a similar population evaluates the PROs as the population who completes the instruments as part of the clinical development program.
Who may be able to join
- ≥ 18 years at the time of consent
- Must have a confirmed diagnosis of COVID-19
- Must have been discharged from hospital due to COVID-19 infection in the last 35 days
- Must exhibit reliability and physiologic capability (e.g. sufficient hearing, vision etc.) to comply with all protocol procedures, in the investigator's opinion and must have educational level of minimum 8th grade or primary school;
- 6. Must be able to read, write, and speak in a local language to complete the informed consent process and participate in an interview; 7. Must be willing to provide written informed consent to participate in the study; and, 8. Must be able to participate in a one-time interview for approximately 90-120 minute via video conference (e.g., Microsoft Teams, WebEx) AND has access to the necessary equipment and internet access.
Who cannot join
- Signed the consent form to participate in the Synairgen SG018 clinical trial,
- Cognitive impairment, significant mental illness, or other disability impairing ability to participate in and/or complete research interview based on study coordinator's or clinician's judgement; or,
- Ongoing substance abuse disorders that may impact participation in this study.
Trial locations and contacts
5 sites in 2 countries.
5 sites in 2 countries
United Kingdom4 sites
Queen Elizabeth Hospital Birmingham
Birmingham, B15 2TH
University Hospitals Dorset NHS Foundation Trust
Bournemouth, Dorset, BH7 7DW
Hull Royal Infirmary
Hull, East Riding Of Yorkshire, HU3 2RW
University Hospital Southampton NHS Foundation Trust
Southampton, Hampshire, SO16 6YD
About this study
Official title: Pilot Test of Clinical Outcome Assessment Methodology (Primarily the Ordinal Scale of Clinical Improvement) and Other Symptom Assessment Patient-reported Outcomes Scales) and Qualitative Evidence of Content Validity
COVID-19 is an acute respiratory disease caused by Severe Acute Respiratory Syndrome coronavirus (SARS-CoV).
Synairgen is currently conducting a global Phase III clinical trial of SNG001 to determine efficacy and safety in patients hospitalised due to COVID-19 that receive oxygen therapy. The primary endpoint in the Phase III trial (SG018) is to evaluate recovery in patients hospitalised due to COVID-19 that require oxygen therapy after administration of SNG001 compared to placebo. The primary endpoint will be determined using the World Health Organization Ordinal Scale of Clinical Improvement (OSCI) score, which will be assessed daily. The OSCI will be used in two different ways during SG018. When the patients are in hospital, the clinical study staff will assess the patient via observation using the OSCI. However, when patients have been discharged from hospital, the clinical study staff will assess the OSCI by asking two questions, one regarding the presence of COVID-19 symptoms and the other regarding usual activities returning to baseline levels. The patient will be required to answer both questions with either a 'yes' or 'no' answer. Daily assessments of the OSCI will be conducted via video call or telephone call after discharge from hospital. The two questions asked of patients when OSCI is assessed after discharge from hospital have been added to trial SG018 to allow assessment of OSCI to continue throughout the trial. As these are new questions and the data from these is being used to assess the primary endpoint in trial SG018, their relevance, ease of understanding and clarity needs to be shown, which is why this interview study is being conducted. Having patients comment on these questions will ensure that the way the benefit of treatment is being measured in SG018 is done in a robust and patient-centred way.
Read more
The main aims of this qualitative pilot study are to:
- To confirm how relevant, clear and easy to understand the two additional OSCI questions asked about COVID-19 symptoms and levels of usual activity are when patients have been discharged from hospital.
- To find out what other symptoms and experiences patients hospitalised for COVID-19 might have had to see if these are reflected in the questionnaires used in SG018.
Read the detailed description
This is non-interventional, qualitative interview study. Patients will participate in a single one-on-one, semi-structured, 90-120 minute interview. The interviews will be audio/video-recorded. The interviews are non treatment-related, and no investigational drugs, devices, or invasive procedures will be administered or evaluated as part of this study.
Patients who have been hospitalized due to COVID-19 will be approached about the study by a dedicated clinician from the site the patient was hospitalized at. Eligible patients will be recruited via hospitals in the UK and the US. At that time, potential participants will be provided with the 'Consent to Contact' form, Patient Information Sheet and Informed Consent Form and if the patient is interested in the study the patient will be asked to sign 'Consent to Contact' form that will allow the clinical staff to pass the patient information to the research team at Parexel. All other research related activities will be conducted by the research team at Parexel.
Parexel research team will contact the potential participants to further confirm eligibility criteria, provide additional details of the study and explain the consent process. Participants will be given ample time to consider the study and the opportunity to ask the research team questions prior to deciding whether to participate or not.
If the participant agrees to take part in the study, the participant will be asked to provide signed consent by signing the Informed Consent Form.
Parexel research team will discuss the most suitable day and time for the interview and will assure that the participant has access to the required technology.
The interview is planned to last between 90-120 minutes and will be audio/video-recorded and transcribed to assure that all important information shared by the participants were captured and that data from the interview can be analysed in a qualitative manner with the use a qualitative data analysis software.
During the interview, the Parexel research team member with expertise in qualitative interviewing will conduct the interviews.
Before the interview begins, the interviewer will again explain the purpose of the study and the interview methodology to each participant. The semi-structured interviews will be conducted in four parts using a semi-structured interview guide.
The first part of the interview will include socio-demographic questions to collect data that can describe the participant interview sample. The following information will be collected: age, gender, nationality, place of residence, race, work status, level of education, general health status, chronic conditions, COVID-19 history including details regarding date of diagnosis, hospitalisation length, oxygenation, perception of COVID-19 severity.
The second part of the interview will be structured to evaluate the validity of the COVID-19 symptom assessment instrument and discharge OSCI via pilot study. Participants will first be asked to complete the instruments as would happen in the SG018 clinical trial. Participants will be asked to complete the PRO instrument using a think-aloud method, whereby participants are encouraged to verbalize their thoughts, while completing the instrument.
In the next step participants will be asked how relevant, clear and easy to understand these instruments were. Ease of completion, comprehensiveness, and appropriateness of the format, response scales, and recall period within the PRO instrument will be evaluated.
The last part of the interview will consist of the concept confirmation exercises where participants will be asked open-ended questions about their experience with COVID-19 to encourage spontaneous responses. This section of the interview guide will include topics, questions, and probes designed to evaluate the concepts collected via other PRO measures used in the Phase III study to confirm their acceptability. The topics covered will include patients' experience of COVID-19 symptoms, fatigue, signs of depression and anxiety, physical pain, impact on physical functioning and daily activities.
- Conditions
- COVID-19
- Keywords
- COVID-19, Ordinal Scale of Clinical Improvement, Clinical Outcome Assessment
- Medical subject headings
- COVID-19
What is being measured
The primary outcome is the main question the study is designed to answer.
Confirmation of content relevance, comprehensiveness and clarity
Confirm the content relevance, comprehensiveness and clarity of the Ordinal Scale of Clinical Improvement (OSCI) score Patient Reported Outcome assessment post hospital discharge. Two questions are answered 'Yes' or 'No' and these determine a score of either 0, 1 or 2, where the higher the score the worse the outcome.
Measured: Within 35 days of hospital discharge
Confirmation of content relevance, comprehensiveness and clarity
Confirm the content relevance, comprehensiveness and clarity of the COVID-19 symptom assessment instrument. When asked if the symptom is present, the patient answers either 'yes' or 'no'. The answer 'yes' indicates a worse outcome.
Measured: Within 35 days of hospital discharge
Confirmation of content relevance for SG018 PRO instruments (BCSS)
Conduct concept confirmation exercises for the breathlessness, cough and sputum scale (BCSS) (scale of 0 (no symptoms) up to 4 (severe symptoms) to demonstrate the content relevance in this patient population.
Measured: Within 35 days of hospital discharge
Confirmation of content relevance for SG018 PRO instruments (EQ-5D-5L)
Conduct concept confirmation exercises for EuroQol 5-dimension 5-level (EQ-5D-5L) to demonstrate the content relevance in this patient population. The EQ-5D-5L provides a simple descriptive profile and a single index value for health status. The EQ-5D-5L self-rated questionnaire includes a visual analogue scale, which records the respondent's self-rated health status on a graduated (0-100) scale, with higher scores for higher health-related quality of life. It also includes the EQ-5D-5L descriptive system, which comprises 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension. Here, 100 means the best health and 0 means the worst health.
Measured: Within 35 days of hospital discharge
Confirmation of content relevance for SG018 PRO instruments (GAD-7)
Conduct concept confirmation exercises for the General Anxiety Disorder 7 Questionnaire (GAD-7) to demonstrate the content relevance in this patient population. Scoring will be done based on how often patients have been bothered by the problems as: feeling nervous, anxious or on edge; not being able to stop or control worrying; worrying too much about different things; trouble relaxing; being so restless that it's hard to sit still; becoming easily annoyed or irritable, and feeling afraid at if something awful might happen. The scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates nearly bothered every day by any of the above problems. Higher scores indicated worse outcome.
Measured: Within 35 days of hospital discharge
Confirmation of content relevance for SG018 PRO instruments (PHQ-9)
Conduct concept confirmation exercises for the Patient Health Questionnaire-9 (PHQ-9) to demonstrate the content relevance in this patient population. Patient health questionnaire included: little interest or pleasure in doing things; feeling down, depressed or hopeless; trouble falling asleep or staying asleep, or sleeping too much; feeling tired or having little energy; poor appetite or overeating; feeling bad about yourself or that you are a failure have let yourself or your family down; trouble concentrating on things; moving or speaking so slowly or so fidgety or restless that you have been moving a lot more than usual; and thoughts that you would be better off dead; or thoughts of hurting yourself in some way. Based on responses, scoring will be done and scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates nearly bothered every day by any of the above problems. Higher scores indicated worse outcome.
Measured: Within 35 days of hospital discharge
Confirmation of content relevance for SG018 PRO instruments (FACIT)
Conduct concept confirmation exercises for the FACIT Fatigue Scale (Version 4) (FACIT) to demonstrate the content relevance in this patient population. The FACIT Fatigue Scale (Version 4) will include statements for patients such as: I feel fatigued; I feel weak all over; I feel listless ("washed out"); I feel tired; I have trouble starting things because I am tired; I have trouble finishing things because I am tired; I have energy; I am able to do my usual activities; I need to sleep during the day; I am too tired to eat; I need help doing my usual activities; and I am frustrated by being too tired to do the things I want to do. Based on responses on above statements, scoring will be done and scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates very much bothered every day by any of the above problems. Higher scores indicated worse outcome.
Measured: Within 35 days of hospital discharge
Confirmation of content relevance for SG018 PRO instruments (BPI-SF)
Conduct concept confirmation exercises for the Brief Pain Inventory (Short Form) (BPI-SF) to demonstrate the content relevance in this patient population. Form includes: did patient have pain other than everyday kinds of pain on assessment day; body part where patient feels pain; rate pain: at worst, at least in the last 24 hours, at average and at right now, by giving scores from 0 to 10, where 0 indicates no pain and 10 represents pain as bad as one can imagine; treatments or medications receiving for pain by patients; how much relief have pain treatments provided from 0% to 100%, where 0% represents no relief and 100% indicates complete relief; assessment of interference of pain in patients activity: general activity; mood; walking ability; normal work; relations with other people; sleep; enjoyment of life, and assessment will be done by scoring ranges from 0 to 10, where 0 represents pain does not interfere and 10 indicates pain completely interferes.
Measured: Within 35 days of hospital discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2022
- Study start15 Nov 2021
- Primary completion31 Jan 2022
- Study completion31 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Other
- Enrolment
- 29 participants (actual)
Sponsor and investigators
- Lead sponsor
- Synairgen Research Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Parexel
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05207293
- Sponsor's protocol ID
- SG019
- Status last verified
- Jan 2023
- First submitted
- 23 Dec 2021
- Last updated
- 4 Jan 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 4 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Test of Clinical Outcome Assessment Methodology (Primarily the Ordinal Scale of Clinical Improvement) and Other Symptom Assessment Patient-reported Outcomes Scales) and Qualitative Evidence of Content Validity
- ClinicalTrials.gov ID
- NCT05207293
- Acronym / sponsor ID
- SG019
- Conditions
- COVID-19
- Keywords
- COVID-19, Ordinal Scale of Clinical Improvement, Clinical Outcome Assessment
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 29 participants (actual)
- Lead sponsor
- Synairgen Research Ltd.Industry (pharma, biotech, devices)
- Collaborators
- Parexel
- Study start
- 15 Nov 2021 (actual)
- Primary completion
- 31 Jan 2022 (actual)
- Study completion
- 31 Jan 2022 (actual)
- First posted
- 26 Jan 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
COVID-19 is an acute respiratory disease caused by Severe Acute Respiratory Syndrome coronavirus (SARS-CoV).
Synairgen is currently conducting a global Phase III clinical trial of SNG001 to determine efficacy and safety in patients hospitalised due to COVID-19 that receive oxygen therapy. The primary endpoint in the Phase III trial (SG018) is to evaluate recovery in patients hospitalised due to COVID-19 that require oxygen therapy after administration of SNG001 compared to placebo. The primary endpoint will be determined using the World Health Organization Ordinal Scale of Clinical Improvement (OSCI) score, which will be assessed daily. The OSCI will be used in two different ways during SG018. When the patients are in hospital, the clinical study staff will assess the patient via observation using the OSCI. However, when patients have been discharged from hospital, the clinical study staff will assess the OSCI by asking two questions, one regarding the presence of COVID-19 symptoms and the other regarding usual activities returning to baseline levels. The patient will be required to answer both questions with either a 'yes' or 'no' answer. Daily assessments of the OSCI will be conducted via video call or telephone call after discharge from hospital. The two questions asked of patients when OSCI is assessed after discharge from hospital have been added to trial SG018 to allow assessment of OSCI to continue throughout the trial. As these are new questions and the data from these is being used to assess the primary endpoint in trial SG018, their relevance, ease of understanding and clarity needs to be shown, which is why this interview study is being conducted. Having patients comment on these questions will ensure that the way the benefit of treatment is being measured in SG018 is done in a robust and patient-centred way.
The main aims of this qualitative pilot study are to:
- To confirm how relevant, clear and easy to understand the two additional OSCI questions asked about COVID-19 symptoms and levels of usual activity are when patients have been discharged from hospital.
- To find out what other symptoms and experiences patients hospitalised for COVID-19 might have had to see if these are reflected in the questionnaires used in SG018.
Detailed description
This is non-interventional, qualitative interview study. Patients will participate in a single one-on-one, semi-structured, 90-120 minute interview. The interviews will be audio/video-recorded. The interviews are non treatment-related, and no investigational drugs, devices, or invasive procedures will be administered or evaluated as part of this study.
Patients who have been hospitalized due to COVID-19 will be approached about the study by a dedicated clinician from the site the patient was hospitalized at. Eligible patients will be recruited via hospitals in the UK and the US. At that time, potential participants will be provided with the 'Consent to Contact' form, Patient Information Sheet and Informed Consent Form and if the patient is interested in the study the patient will be asked to sign 'Consent to Contact' form that will allow the clinical staff to pass the patient information to the research team at Parexel. All other research related activities will be conducted by the research team at Parexel.
Parexel research team will contact the potential participants to further confirm eligibility criteria, provide additional details of the study and explain the consent process. Participants will be given ample time to consider the study and the opportunity to ask the research team questions prior to deciding whether to participate or not.
If the participant agrees to take part in the study, the participant will be asked to provide signed consent by signing the Informed Consent Form.
Parexel research team will discuss the most suitable day and time for the interview and will assure that the participant has access to the required technology.
The interview is planned to last between 90-120 minutes and will be audio/video-recorded and transcribed to assure that all important information shared by the participants were captured and that data from the interview can be analysed in a qualitative manner with the use a qualitative data analysis software.
During the interview, the Parexel research team member with expertise in qualitative interviewing will conduct the interviews.
Before the interview begins, the interviewer will again explain the purpose of the study and the interview methodology to each participant. The semi-structured interviews will be conducted in four parts using a semi-structured interview guide.
The first part of the interview will include socio-demographic questions to collect data that can describe the participant interview sample. The following information will be collected: age, gender, nationality, place of residence, race, work status, level of education, general health status, chronic conditions, COVID-19 history including details regarding date of diagnosis, hospitalisation length, oxygenation, perception of COVID-19 severity.
The second part of the interview will be structured to evaluate the validity of the COVID-19 symptom assessment instrument and discharge OSCI via pilot study. Participants will first be asked to complete the instruments as would happen in the SG018 clinical trial. Participants will be asked to complete the PRO instrument using a think-aloud method, whereby participants are encouraged to verbalize their thoughts, while completing the instrument.
In the next step participants will be asked how relevant, clear and easy to understand these instruments were. Ease of completion, comprehensiveness, and appropriateness of the format, response scales, and recall period within the PRO instrument will be evaluated.
The last part of the interview will consist of the concept confirmation exercises where participants will be asked open-ended questions about their experience with COVID-19 to encourage spontaneous responses. This section of the interview guide will include topics, questions, and probes designed to evaluate the concepts collected via other PRO measures used in the Phase III study to confirm their acceptability. The topics covered will include patients' experience of COVID-19 symptoms, fatigue, signs of depression and anxiety, physical pain, impact on physical functioning and daily activities.
Study design
- Observational model
- Other
- Time perspective
- Other
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study will include up to 25 patients who have had a positive test for COVID-19 and who were hospitalised due to their COVID-19. Diagnosis of COVID-19 and hospitalization will be confirmed by study personnel. The interview will take place up to 35 days post discharge from hospital. The eligibility criteria are designed to align with the SG018 protocol to ensure that a similar population evaluates the PROs as the population who completes the instruments as part of the clinical development program.
Key inclusion criteria (5 listed)
- ≥ 18 years at the time of consent
- Must have a confirmed diagnosis of COVID-19
- Must have been discharged from hospital due to COVID-19 infection in the last 35 days
- Must exhibit reliability and physiologic capability (e.g. sufficient hearing, vision etc.) to comply with all protocol procedures, in the investigator's opinion and must have educational level of minimum 8th grade or primary school;
- 6. Must be able to read, write, and speak in a local language to complete the informed consent process and participate in an interview; 7. Must be willing to provide written informed consent to participate in the study; and, 8. Must be able to participate in a one-time interview for approximately 90-120 minute via video conference (e.g., Microsoft Teams, WebEx) AND has access to the necessary equipment and internet access.
Key exclusion criteria (3 listed)
- Signed the consent form to participate in the Synairgen SG018 clinical trial,
- Cognitive impairment, significant mental illness, or other disability impairing ability to participate in and/or complete research interview based on study coordinator's or clinician's judgement; or,
- Ongoing substance abuse disorders that may impact participation in this study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Confirmation of content relevance, comprehensiveness and clarity
Time frame: Within 35 days of hospital discharge
Confirm the content relevance, comprehensiveness and clarity of the Ordinal Scale of Clinical Improvement (OSCI) score Patient Reported Outcome assessment post hospital discharge. Two questions are answered 'Yes' or 'No' and these determine a score of either 0, 1 or 2, where the higher the score the worse the outcome.
Confirmation of content relevance, comprehensiveness and clarity
Time frame: Within 35 days of hospital discharge
Confirm the content relevance, comprehensiveness and clarity of the COVID-19 symptom assessment instrument. When asked if the symptom is present, the patient answers either 'yes' or 'no'. The answer 'yes' indicates a worse outcome.
Confirmation of content relevance for SG018 PRO instruments (BCSS)
Time frame: Within 35 days of hospital discharge
Conduct concept confirmation exercises for the breathlessness, cough and sputum scale (BCSS) (scale of 0 (no symptoms) up to 4 (severe symptoms) to demonstrate the content relevance in this patient population.
Confirmation of content relevance for SG018 PRO instruments (EQ-5D-5L)
Time frame: Within 35 days of hospital discharge
Conduct concept confirmation exercises for EuroQol 5-dimension 5-level (EQ-5D-5L) to demonstrate the content relevance in this patient population. The EQ-5D-5L provides a simple descriptive profile and a single index value for health status. The EQ-5D-5L self-rated questionnaire includes a visual analogue scale, which records the respondent's self-rated health status on a graduated (0-100) scale, with higher scores for higher health-related quality of life. It also includes the EQ-5D-5L descriptive system, which comprises 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension. Here, 100 means the best health and 0 means the worst health.
Confirmation of content relevance for SG018 PRO instruments (GAD-7)
Time frame: Within 35 days of hospital discharge
Conduct concept confirmation exercises for the General Anxiety Disorder 7 Questionnaire (GAD-7) to demonstrate the content relevance in this patient population. Scoring will be done based on how often patients have been bothered by the problems as: feeling nervous, anxious or on edge; not being able to stop or control worrying; worrying too much about different things; trouble relaxing; being so restless that it's hard to sit still; becoming easily annoyed or irritable, and feeling afraid at if something awful might happen. The scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates nearly bothered every day by any of the above problems. Higher scores indicated worse outcome.
Confirmation of content relevance for SG018 PRO instruments (PHQ-9)
Time frame: Within 35 days of hospital discharge
Conduct concept confirmation exercises for the Patient Health Questionnaire-9 (PHQ-9) to demonstrate the content relevance in this patient population. Patient health questionnaire included: little interest or pleasure in doing things; feeling down, depressed or hopeless; trouble falling asleep or staying asleep, or sleeping too much; feeling tired or having little energy; poor appetite or overeating; feeling bad about yourself or that you are a failure have let yourself or your family down; trouble concentrating on things; moving or speaking so slowly or so fidgety or restless that you have been moving a lot more than usual; and thoughts that you would be better off dead; or thoughts of hurting yourself in some way. Based on responses, scoring will be done and scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates nearly bothered every day by any of the above problems. Higher scores indicated worse outcome.
Confirmation of content relevance for SG018 PRO instruments (FACIT)
Time frame: Within 35 days of hospital discharge
Conduct concept confirmation exercises for the FACIT Fatigue Scale (Version 4) (FACIT) to demonstrate the content relevance in this patient population. The FACIT Fatigue Scale (Version 4) will include statements for patients such as: I feel fatigued; I feel weak all over; I feel listless ("washed out"); I feel tired; I have trouble starting things because I am tired; I have trouble finishing things because I am tired; I have energy; I am able to do my usual activities; I need to sleep during the day; I am too tired to eat; I need help doing my usual activities; and I am frustrated by being too tired to do the things I want to do. Based on responses on above statements, scoring will be done and scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates very much bothered every day by any of the above problems. Higher scores indicated worse outcome.
Confirmation of content relevance for SG018 PRO instruments (BPI-SF)
Time frame: Within 35 days of hospital discharge
Conduct concept confirmation exercises for the Brief Pain Inventory (Short Form) (BPI-SF) to demonstrate the content relevance in this patient population. Form includes: did patient have pain other than everyday kinds of pain on assessment day; body part where patient feels pain; rate pain: at worst, at least in the last 24 hours, at average and at right now, by giving scores from 0 to 10, where 0 indicates no pain and 10 represents pain as bad as one can imagine; treatments or medications receiving for pain by patients; how much relief have pain treatments provided from 0% to 100%, where 0% represents no relief and 100% indicates complete relief; assessment of interference of pain in patients activity: general activity; mood; walking ability; normal work; relations with other people; sleep; enjoyment of life, and assessment will be done by scoring ranges from 0 to 10, where 0 represents pain does not interfere and 10 indicates pain completely interferes.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jan 2023.
- Individual participant dataSharing planned: Undecided
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
5 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19, run by Synairgen Research Ltd. at 5 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United Kingdom, United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Confirmation of content relevance, comprehensiveness and clarity (time frame: Within 35 days of hospital discharge). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jan 2023.